UK Innovation Map
Compare placesDifferent, not ranked.
Two or three clusters, read side by side across sectors, research, companies, capital, infrastructure, government designations and UKIZ relevance. There is no score and no ranking: British clusters are different from one another, not better or worse than one another.
Choose up to three clusters
- London
- Cambridge
- Oxford
- Manchester
- Birmingham & the West Midlands
- Bristol & Bath
- Sheffield & Rotherham
- Leeds & West Yorkshire
- Liverpool City Region
- Newcastle & the North East
- Teesside & the Humber
- Edinburgh
- Glasgow & the Central Belt
- Belfast
- Cardiff & South Wales
- Southampton & Portsmouth
- Cornwall & Plymouth
- Nottingham & Derby
- Norwich & the East
Side by side
| Dimension | Leeds & West YorkshireYorkshire and the Humber | EdinburghScotland | CambridgeEast of England |
|---|---|---|---|
| Sectors | Life Sciences, Digital Technologies, Financial Technology Supporting: Artificial Intelligence, Advanced Manufacturing, Creative Industries | Artificial Intelligence, Financial Technology, Robotics & Autonomous Systems, Digital Technologies Supporting: Engineering Biology, Life Sciences, Quantum Technologies, Creative Industries | Life Sciences, Semiconductors, Engineering Biology, Artificial Intelligence Supporting: Quantum Technologies, Advanced Materials, AgriTech & FoodTech, Digital Technologies |
| Research |
|
|
|
| Companies |
|
|
|
| Infrastructure | Not recorded on the map. Health data infrastructure, teaching hospitals and university research facilities. |
Informatics research facilities, robotics commercialisation facilities and supercomputing capability. |
University and institute laboratories, genomics and biomedical campus facilities, and semiconductor design capability. |
| Capital | Financial services depth locally, but early-stage health technology capital remains limited. | Large institutional asset management presence; venture activity is smaller than the capital base implies. | Specialist deep tech and life science funds, university-linked funds, and corporate partners; strong at seed, thinner at growth stage relative to demand. |
| Government programmes | No place-based designation recorded. | No place-based designation recorded. | No place-based designation recorded. |
| What exists | National health data organisations, medical technology, a large financial and professional services base and a research university with data and materials strength. | One of Europe's largest informatics research bases, robotics and autonomous systems commercialisation capability, and a substantial asset management, banking and financial technology sector. | Extreme research density for its size: life sciences and genomics, semiconductor and processor IP, engineering biology and AI, with a mature spin-out culture and specialist investors who understand long timelines. |
| What's missing · UKIZ interpretation | A clear route for companies to work with health data at scale, and clinical adoption pathways that move faster than pilot projects. | A connection between the capital sitting in Edinburgh's financial institutions and the technology being created a mile away; and later-stage funding to stop companies relocating south. | Ownership retention. Discovery and early company formation work; the Series B onward stage frequently transfers ownership overseas. Laboratory and scale-up space, power and housing also constrain growth. |
| What could connect · UKIZ interpretation | Leeds health data capability connected to Manchester clinical research and to medical technology manufacturing, giving companies discovery, evidence and production in one region. | Scottish institutional capital connected to Scottish deep tech, and Edinburgh AI and robotics capability connected to Glasgow manufacturing and satellite production. | Cambridge discovery connected to UK manufacturing and biomanufacturing capacity, and to later-stage domestic capital, so that value created here is realised here rather than acquired out of the country. |
| UKIZ relevance | Health data at population scale is a national asset. The proposed Manchester mission and Leeds capability are complementary rather than competing. | Scotland's research strength is not in question; its scale-up retention is. The proposed Scotland mission focuses on the capital and customer layer. | Cambridge produces intellectual property at a rate few places match, and loses ownership of too much of it at Series B. The proposed Oxford-Cambridge zone concentrates on commercialisation and retention rather than on more discovery. |
| Last verified | 15 August 2026 | 15 August 2026 | 15 August 2026 |
Proposed by UKIZ · independent · not a government designation